<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T01:17:58Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/10122" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/10122</identifier><datestamp>2026-10-18T21:13:06Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Probiotics as an alternative to eliminate Pseudomonas aeruginosa biofilm</dc:title><dc:creator>Celebi, Selahattin</dc:creator><dc:creator>Celebi, Ozgur</dc:creator><dc:creator>Celebi, Demet</dc:creator><dc:creator>Baser, Sumeyye</dc:creator><dc:creator>Dabanlioglu, Bulent</dc:creator><dc:creator>Ektas Kalayci, Sila</dc:creator><dc:creator>Aslan, Sumeyye</dc:creator><dc:creator>Islamoglu, Fatma</dc:creator><dc:creator>Taghizadehghalehjoughi, Ali</dc:creator><dc:subject>Antibiotic resistance</dc:subject><dc:subject>Biofilm</dc:subject><dc:subject>Lacticaseibacillus rhamnosus</dc:subject><dc:subject>Pseudomonas aeruginosa</dc:subject><dc:subject>Anti-Bacterial Agents</dc:subject><dc:subject>Biofilms</dc:subject><dc:subject>Drug Resistance, Bacterial</dc:subject><dc:subject>Humans</dc:subject><dc:subject>Microbial Sensitivity Tests</dc:subject><dc:subject>Probiotics</dc:subject><dc:subject>Pseudomonas Infections</dc:subject><dc:subject>amikacin</dc:subject><dc:subject>ampicillin</dc:subject><dc:subject>avibactam plus ceftazidime</dc:subject><dc:subject>aztreonam</dc:subject><dc:subject>cefepime</dc:subject><dc:subject>ceftazidime</dc:subject><dc:subject>ceftriaxone</dc:subject><dc:subject>cefuroxime</dc:subject><dc:subject>cefuroxime axetil</dc:subject><dc:subject>ciprofloxacin</dc:subject><dc:subject>cotrimoxazole</dc:subject><dc:subject>imipenem</dc:subject><dc:subject>meropenem</dc:subject><dc:subject>piperacillin plus tazobactam</dc:subject><dc:subject>probiotic agent</dc:subject><dc:subject>tigecycline</dc:subject><dc:subject>antiinfective agent</dc:subject><dc:subject>algD gene</dc:subject><dc:subject>antibiofilm activity</dc:subject><dc:description>Pseudomonas aeruginosa is a clinically important opportunistic pathogen characterized by high antibiotic resistance and strong biofilm-forming capacity, posing a major therapeutic challenge, particularly in immunocompromised patients. In this study, we aimed to evaluate the antibiotic resistance profiles and biofilm-forming abilities of clinical isolates, and to investigate the antibiofilm potential of the probiotic strain Lacticaseibacillus rhamnosus. A total of 66 clinical isolates were analyzed, revealing high levels of antibiotic resistance, while 87.9% of isolates demonstrated biofilm-forming capacity. Treatment with L. rhamnosus at 25% and 50% concentrations resulted in significant antimicrobial and antibiofilm effects. MIC and antibiofilm assays indicated that these effects were dose- and cell density-dependent. Scanning electron microscopy analyses confirmed the structural disruption of biofilms following treatment. Furthermore, real-time PCR results demonstrated that the expression levels of key biofilm-associated genes (algD, pelF, pslD, ppgl, and PAPI-1) were reduced by more than 50%. Importantly, this study provides evidence that L. rhamnosus can effectively inhibit both biofilm formation and biofilm-associated gene expression in multidrug-resistant P. aeruginosa isolates, highlighting its potential as a promising alternative or adjunctive biocontrol strategy against biofilm-related infections. These findings contribute to the growing body of research on probiotic-based approaches targeting antimicrobial resistance and biofilm-associated pathogenicity. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2026.</dc:description><dc:publisher>Springer Science and Business Media Deutschland GmbH</dc:publisher><dc:date>2026</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/10122</dc:identifier><dc:identifier>https://doi.org/10.1007/s10482-026-02391-x</dc:identifier><dc:identifier>0003-6072</dc:identifier><dc:language>en</dc:language><dc:relation>Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/10122</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>